biomodal, the omics-based life sciences technology company, has announced the expansion of the reach of its duet multiomic solutions with a partnership with Element Biosciences.

 

Validated at the University of Minnesota (UMN) Genomics Center, the integration promises heightened sensitivity for cancer, aging, and neurodegenerative disease research, aiming to accelerate clinical breakthroughs.

 

The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC, with Element’s platforms --  AVITI24 5D multiomics and AVITI sequencing instruments -- extending complete methylation detection to Element users. 

 

Researchers can now transform next-generation sequencing (NGS) data into actionable insights in a single, streamlined workflow. AVITI and AVITI24 operators also gain access to biomodal’s software pipeline, expanding analytical capabilities while biomodal explores compatibility with future Element systems.

 

“By combining biomodal’s duet multiomic solutions with the Element AVITI system, our clients gain insights into disease processes that are not accessible without a 6-base genome,” said Kenny Beckman, Director of the UMN Genomics Center. “We're excited to extend this capability to our researchers as they work to uncover a deeper mechanistic understanding of disease.”

 

Peter Fromen, CEO of biomodal, added, “We designed our technology to be platform agnostic to ensure researchers have access to the highest quality multiomic data. Through this partnership with Element, we are excited to deliver the novel benefits of biomodal’s duet multiomic solutions to better support life sciences customers worldwide.”